---
schema_version: "secwatch.filing_event.v1"
accession: "0001055726-24-000053"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:12:20.002566+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inovio Q3 net loss $25.2M; INO-3107 BLA on track for mid-2025 submission

## Summary
- Net loss of $25.2M ($0.89/share) vs $33.9M loss in Q3 2023; R&D expense $18.7M, G&A $8.6M.
- Cash, equivalents and short-term investments $84.8M at Sept 30, 2024; cash runway into Q3 2025.
- INO-3107 Phase 1/2 data: 81% of 32 patients had fewer surgeries; 28% had zero surgeries post-treatment.
- All non-device BLA modules for INO-3107 on track for completion by year-end 2024; BLA submission targeted mid-2025.
- Advancing Phase 3 plan for INO-3112 in HPV+ throat cancer; Phase 2 Ebola vaccine booster trial in FDA discussions.

## SEC filing metadata
- accession: 0001055726-24-000053
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000053/0001055726-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000053/ino-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001055726-24-000053
- JSON: https://secwatch.observer/filing/0001055726-24-000053.json
- Plain text: https://secwatch.observer/filing/0001055726-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.